NYSE:BELLUS Health Inc.

График котировок BELLUS Health Inc.


Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания

Основные параметры

P/S 10.19
P/BV 2.17
EV/EBITDA -5.25
Цена ао 3.1119

Похожие компании

Описание BELLUS Health Inc.

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.